Drug intelligence / Profile preview

Resolvine

Development stage: Phase 1
Lead developer: Kato Pharmaceuticals
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravitreal, Ophthalmic

Overview

Resolvine is an investigational pharmacologic vitreolysis agent developed by Kato Pharmaceuticals for the treatment of symptomatic vitreomacular attachment (VMA), vitreomacular traction, and non-proliferative diabetic retinopathy (NPDR). The drug is a liposomal formulation of urea, designed for intravitreal injection. Its mechanism of action involves the chemical disruption of protein-mediated adhesions at the vitreoretinal interface, facilitating the separation of the vitreous from the macula (posterior vitreous detachment). By inducing this separation non-surgically, Resolvine aims to improve visual outcomes and reduce the need for invasive vitrectomy procedures.

Brand names: Resolvine
Other names: urealiposomal urea

Beyond the preview

Go deeper on Resolvine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resolvine.